Salarius Pharmaceuticals, Inc. — Cyborg Score 4/10
Mixed
Peptide-conjugate oncology therapeutics
Strategic Profile
Salarius has undergone a significant strategic transformation through its merger with Decoy Therapeutics Inc. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company faces significant execution risk as a pre-revenue clinical-stage asset with early-stage pipeline programs.
Cyborg Score Rationale
Nasdaq delisting determination over bid price deficiency was sparked in January 2026. The company maintains clinical-stage assets in oncology but operates at micro-cap scale with negative operating cash flow. The strategic pivot to peptide conjugates via Decoy merger adds platform optionality, but execution and capital availability remain key risks.
Top Insights
The corporate name changed to Decoy Therapeutics Inc. and the Nasdaq ticker symbol changed to DCOY, with trading under DCOY scheduled to begin January 8, 2026.
Lead candidate seclidemstat (SP-2577) is being studied as treatment for pediatric cancers.
Seclidemstat is being studied in an investigator-initiated Phase 1/2 clinical study in hematologic cancers at MD Anderson Cancer Center for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).
The company was founded in February 2014 and is headquartered in Houston, TX.
Named Competitors
Protein Degradation Therapeutics — Established oncology and targeted protein degradation
Adaptive T-cell Therapy — Immune-oncology and next-generation cell therapy
Targeted Cancer Therapeutics — Oncology-focused targeted molecular therapeutics
Recent Developments
(January 2026) Changed corporate name to Decoy Therapeutics and ticker symbol to DCOY reflecting strategic focus on peptide-conjugate therapeutics
(January 2026) Received Nasdaq delisting determination over bid price deficiency and announced intention to appeal
(December 2025) Announced planned corporate name change and ticker symbol change
Open the full interactive Salarius Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.